CSIMarket
 
Ocular Therapeutix Inc   (OCUL)
Other Ticker:  
 
 
Price: $9.9000 $0.04 0.406%
Day's High: $10.5499 Week Perf: 31.65 %
Day's Low: $ 9.56 30 Day Perf: 130.77 %
Volume (M): 3,155 52 Wk High: $ 10.55
Volume (M$): $ 31,236 52 Wk Avg: $4.58
Open: $10.00 52 Wk Low: $2.00



 Market Capitalization (Millions $) 843
 Shares Outstanding (Millions) 85
 Employees -
 Revenues (TTM) (Millions $) 58
 Net Income (TTM) (Millions $) -67
 Cash Flow (TTM) (Millions $) -10
 Capital Exp. (TTM) (Millions $) 8

Ocular Therapeutix Inc
Ocular Therapeutix Inc is a pharmaceutical company that specializes in the development and commercialization of innovative therapies for diseases and conditions affecting the eye. They focus on creating sustained-release drug delivery systems to improve the effectiveness and convenience of eye treatments. Their products aim to address various ocular disorders such as glaucoma, dry eye disease, and allergic conjunctivitis. Ocular Therapeutix aims to provide patients with long-lasting and efficient treatments that reduce the need for frequent medication administration.


   Company Address: 24 Crosby Drive Bedford 1730 MA
   Company Phone Number: 357-4000   Stock Exchange / Ticker: NASDAQ OCUL
   OCUL is expected to report next financial results on March 05, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Stock Market Announcement

Ocular Therapeutix Grants Inducement Awards to Newly Appointed Executives, Symbolic of Continued Company Growth and Commitment to Advancing Ophthalmic Therapies

Published Thu, Feb 22 2024 12:32 PM UTC


Ocular Therapeutix has been making significant strides in the ophthalmic field, and the addition of Dr. Dugel and Dr. Nayak to their executive team further strengthens the company's expertise and strategic vision. This move reflects Ocular's commitment to attracting top talent in the industry in order to advance the development and commercialization of groundbreaking oc...

Dividend

Ocular Therapeutix Raises $325 Million in Private Placement to Advance Vision-Enhancing Therapies

Published Thu, Feb 22 2024 12:31 PM UTC



Ocular Therapeutix, Inc. has made headlines yet again with its latest announcement of securing $325 million in a private placement deal. The Massachusetts-based biopharmaceutical company has successfully entered into a securities purchase agreement with several institutional accredited investors, aiming to accelerate the development and commercialization of innovat...

Clinical Study

Shaping the Future of AMD Treatment: Ocular Therapeutix's AXPAXLI Intravitreal Implant Holds Promise in Pivotal Phase 3 SOL-1 Study

Published Tue, Feb 13 2024 12:38 PM UTC

Ocular Therapeutix's AXPAXLI Shows Promise for Treating Wet Age-related Macular Degeneration: A Comprehensive Review of the Phase 3 SOL-1 StudyOcular Therapeutix recently announced the initiation of the Phase 3 SOL-1 study, which aims to evaluate the efficacy and safety of their investigational drug, AXPAXLI, in treating wet age-related macular degeneration (AMD). This key m...

Clinical Study

Enhancing Patient Eligibility and Improving Outcomes: FDA Amends Special Protocol Assessment for AXPAXLI in Wet AMD Clinical Trial

Published Thu, Jan 25 2024 1:00 PM UTC

The treatment landscape for wet age-related macular degeneration (Wet AMD) is constantly evolving, with researchers and medical professionals striving to develop more effective and patient-friendly therapeutic options. Among these advancements, Ocular Therapeutix has recently announced a significant breakthrough in their ongoing clinical trial for AXPAXLI, a promising treatm...

Financing Agreement

Ocular Therapeutix Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters ?? Catalyzing the Future of Eye Care Innovations

Published Mon, Dec 18 2023 9:01 PM UTC

Ocular Therapeutix Announces Successful Closure of Public Offering: A Milestone towards Advancing Innovations in Eye Therapies
BEDFORD, Mass., Dec. 18, 2023 - Ocular Therapeutix, Inc. (Nasdaq: OCUL), a leading biopharmaceutical company specializing in the formulation, development, and commercialization of revolutionary therapies for various eye diseases and conditions, p...






 

Ocular Therapeutix Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com